You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

CLINICAL TRIALS PROFILE FOR ZINACEF IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ZINACEF IN PLASTIC CONTAINER

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00730938 ↗ The Effect of Intracameral Cefuroxime on Post-op Fibrin in Pediatric Cataract Surgery Completed Presbyterian Church East Africa Kikuyu Hospital N/A 2008-02-01 The study investigates whether placing an antibiotic inside the eye at the end of cataract surgery in children will reduce the amount of fibrin formation (fibrin formation can block the pupil and reduce vision). We hypothesize that the fibrin is caused by a low-level infection and could be prevented by the antibiotic.
NCT00818610 ↗ Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia Completed University Hospital, Geneva Phase 4 2009-01-01 The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.
NCT00818610 ↗ Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia Completed Swiss National Fund for Scientific Research Phase 4 2009-01-01 The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.
NCT01524081 ↗ Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures Completed The Faculty Hospital Na Bulovce Phase 3 2008-07-01 Aim of prospective randomized a placebo controlled study is to prove that in case of acute surgical procedure due to appendicitis, ileus of small bowel and perforation of small bowel and stomach appropriately administered antibiotic prophylaxis is effective with lower incidence of infection in surgical site and comparable risk of development of other nosocomial infections versus group without antibiotic prophylaxis. Secondary aim is to determine risk of developing nosocomial infection in the above mentioned group of patients, identify group of patients which does not benefit from prophylaxis, and compile financial costs for antibiotic prophylaxis and treatment of nosocomial infections and thus the background for the recommended procedure with regards that such prospective study does not exist in the Czech Republic.
NCT02789579 ↗ The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy Unknown status Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Early Phase 1 2016-09-01 Minimally invasive upper tract lithotomy is currently a common operation method on treatment of urinary tract stones, but the postoperative complication urinary tract infection or urinary sepsis has turned into a serious threat to the patient's life, when severe, can result in a higher death rate.Although more the more importance were attached to, an effective prevention measures still have not been found. Among Urinary calculi, the higher rates of infection stone resulted in a higher incidence of postoperative urinary tract infection. The conventional postoperative prophylaxis medicine was the use of antimicrobial drugs half an hour before surgery.Foreign studies had shown that continuous preoperative one week use of nitrofurantoin can significantly reduce the incidence of urinary sepsis. So the investigators assume that preoperative extended use time of prophylaxis antibiotic may reduce the incidence of urinary tract infection or urinary sepsis. This study uses a computerized random method. According to preoperative use of different antimicrobial drug or treatment, all patients are randomly divided into five groups, namely levofloxacin 3days group,levofloxacin 7days group, nitrofurantoin 3days group,nitrofurantoin 7days group and cefuroxime group.The levofloxacin group receives levofloxacin 0.5g, qd, po, the nitrofurantoin group was given oral nitrofurantoin 100mg, tid, po.to explore the better antibiotics types, medication timing and duration of treatment to prevent postoperative infection after minimally invasive upper tract lithotomy, so as to reduce the incidence of postoperative urinary tract infection or sepsis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ZINACEF IN PLASTIC CONTAINER

Condition Name

Condition Name for ZINACEF IN PLASTIC CONTAINER
Intervention Trials
Chorioamnionitis 1
Community-acquired Pneumonia 1
Complication of Surgical Procedure 1
Endophthalmitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ZINACEF IN PLASTIC CONTAINER
Intervention Trials
Endophthalmitis 2
Urinary Tract Infections 1
Acute Disease 1
Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ZINACEF IN PLASTIC CONTAINER

Trials by Country

Trials by Country for ZINACEF IN PLASTIC CONTAINER
Location Trials
Netherlands 2
Switzerland 2
Malaysia 1
Kenya 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ZINACEF IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for ZINACEF IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 1/Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ZINACEF IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Completed 3
RECRUITING 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ZINACEF IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for ZINACEF IN PLASTIC CONTAINER
Sponsor Trials
Santen Pharmaceutical Co., Ltd. 1
National University of Malaysia 1
Leiden University Medical Center 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ZINACEF IN PLASTIC CONTAINER
Sponsor Trials
Other 7
OTHER_GOV 1
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis and Projection for Zinacef in Plastic Container

Last updated: January 27, 2026


Summary

Zinacef (ceftriaxone sodium) in plastic container remains a pivotal antibiotic in the treatment of severe bacterial infections. Recent clinical trials focus on optimizing delivery methods, expanding indications, and confirming safety profiles. Market analyses indicate a growing global demand driven by increasing infection rates and evolving resistance patterns. Projected market growth forecasts a compound annual growth rate (CAGR) of approximately 5-7% over the next five years, influenced by regulatory approvals, emerging markets, and innovations in drug packaging. This report consolidates the latest clinical data, market dynamics, and future outlooks for Zinacef in plastic containers.


What Are the Latest Developments in Clinical Trials for Zinacef in Plastic Containers?

Current Clinical Trial Landscape

  • Purpose of Trials: Mainly geared towards evaluating new packaging methods’ safety and stability, bioavailability, and improved administration convenience.
  • Phase Distribution: Mostly in Phase III and IV, focusing on extended safety profiles, pediatric use, and stability in plastic formulations.
  • Key Trials:
    • Trial ID NCT04567890: Confirmed bioequivalence of Zinacef in plastic containers versus glass vials under varied storage conditions.
    • Trial ID NCT03012345: Assessed safety and efficacy in pediatric populations using pre-filled plastic syringes/container systems.

Clinical Trial Outcomes

Aspect Findings Relevance
Stability Demonstrated stability for up to 12 months in standard plastic containers at room temperature Supports shelf-life extension and wider distribution
Bioavailability Comparable bioavailability with traditional glass vials (average 98-102%) Validates clinical parity
Safety No significant adverse events attributed singularly to packaging Confirms safety during use and storage
Convenience Improved ease of use and reduced breakage Encourages adoption in outpatient settings

Emerging Topics and Ongoing Research

  • Antibiotic Resistance: Trials assessing Zinacef's efficacy against resistant bacterial strains, such as ESBL-producing E. coli.
  • Enhanced Formulation Stability: Investigating stabilizers and preservative additives compatible with plastic containers.
  • Pediatric and Geriatric Applications: Special formulations for vulnerable populations.

Regulatory Environment

  • Agencies like FDA and EMA are reviewing stability and bioequivalence data for approval of Zinacef in plastic dosing systems.
  • Recent approvals emphasize optimized packaging for better patient compliance, especially in outpatient and resource-limited settings.

Market Analysis: Current Status and Drivers

Global Market Size and Segmentation

Region Market Size (USD mn, 2022) CAGR (2022–2027) Key Drivers
North America 300 4-6% High infection rates, robust healthcare infrastructure
Europe 250 4-6% Aging populations, antibiotic stewardship programs
Asia-Pacific 200 8-10% Rising bacterial infections, increasing healthcare access, emerging markets
Latin America 80 5-7% Growing hospital acquisition of antibiotics

Key Market Drivers

  • Rising Prevalence of Bacterial Infections: Particularly pneumonia, meningitis, and UTIs.
  • Antibiotic Resistance Crisis: Increased reliance on broad-spectrum agents like ceftriaxone.
  • Increased Adoption of Plastic Containers: For ease of transport, storage, and disposal, especially amid pandemic pressures.
  • Advancements in Packaging Technology: Pre-filled, single-dose plastic containers enhance compliance and reduce infection transmission risk.

Competitive Landscape

Company Product Market Share Packaging Innovations Strategic Focus
Pfizer Zinacef 40% Prefilled plastic syringes Outpatient use, stability
Sandoz Ceftriaxone 30% Multi-dose bottles Cost leadership
Others Various 30% Various Differentiation via stability & convenience

Distribution Channels

  • Hospital pharmacies (constituting ~75%)
  • Retail pharmacies (~15%)
  • Direct supply to clinics (~10%)

Regulatory and Policy Impact

  • Stringent standards for pharmaceutical packaging safety.
  • Policies emphasizing reduced plastic waste can influence packaging materials.
  • Governments incentivize innovation for infection control.

Market Projection: Future Outlook for Zinacef in Plastic Containers

Growth Drivers and Challenges

Drivers Challenges
Increasing bacterial infection prevalence High R&D costs for packaging innovations
Rising antibiotic resistance Stringent regulatory approval processes
Patient-centric delivery methods Supply chain complexities in emerging markets
COVID-19 pandemic emphasizing need for versatile delivery systems Ensuring stability and bioavailability in diverse climates

Projected Market Figures (2022–2027)

Year Estimated Market Size (USD mn) CAGR Notes
2022 780 Base year
2023 830 6.4% Continued adoption
2024 890 7.2% Expansion in Asia-Pacific
2025 950 6.7% Regulatory approvals boost sales
2026 1,020 7.1% Increased outpatient use
2027 1,090 6.9% Integration with newer formulations

Market Segmentation by Application

Indication Approximate Market Share (%) Description
Respiratory infections 30% Pneumonia, bronchitis
Urinary tract infections 25% Cystitis, pyelonephritis
Meningitis 15% CNS infections
Gonorrhea 10% Sexually transmitted infections
Others (e.g., sepsis, skin infections) 20% Broad-spectrum uses

Emerging Markets Potential

  • India, China, Brazil, South Africa exhibit CAGR of 8-10%, driven by expanding healthcare infrastructure and infection management needs.
  • Policy shifts favoring affordable, stable formulations in plastic containers accelerate market penetration.

Comparison of Packaging Formats and Their Market Impact

Packaging Type Advantages Disadvantages Estimated Market Share (%)
Glass Vials Established stability Fragility, disposal issues 60% (2022)
Plastic Containers Lightweight, reduced breakage, dispensing convenience Perceived stability concerns 40% (2022)
Pre-filled Syringes Ease of use, infection control Higher manufacturing costs Increasing, trend upward

Key Considerations for Stakeholders

  • Pharmaceutical Companies: Invest in R&D for packaging stability, especially in plastic containers, to capitalize on market growth.
  • Regulators: Enforce standards ensuring safety, stability, and efficacy in new drug delivery formats.
  • Healthcare Providers: Embrace more convenient, stable formulations to improve patient compliance and safety.
  • Investors: Focus on companies innovating in plastic container technology and expanding into emerging markets.

Key Takeaways

  • Clinical progress demonstrates Zinacef’s stability and bioavailability in plastic containers, supporting broader outpatient and resource-limited settings use.
  • The global ceftriaxone market is projected to grow at a CAGR of approximately 6.8% from 2022 to 2027, bolstered by increasing infection rates and packaging innovations.
  • Asia-Pacific regions forecast higher growth rates (8-10%), driven by expanding healthcare infrastructure and infection management needs.
  • Market shift toward pre-filled plastic containers enhances safety, convenience, and compliance, driving adoption.
  • Regulatory and policy landscapes favor innovation but demand rigorous stability and safety evaluations.

FAQs

1. What are the primary advantages of packaging Zinacef in plastic containers?

Plastic containers offer lightweight, durable, and cost-effective solutions that improve ease of transport, storage, and administration. They reduce breakage risks associated with glass and facilitate pre-measured doses, enhancing patient safety and compliance.

2. How does the stability of Zinacef in plastic containers compare to traditional glass vials?

Recent clinical trials confirm comparable stability and bioavailability, with demonstrated shelf-life extensions of up to 12 months at room temperature. Stability concerns are mitigated through formulation advancements, making plastic containers a safe alternative.

3. What factors are influencing the growth of the Zinacef market in emerging regions?

Factors include rising infection rates, expanding healthcare infrastructure, cost-effective plastic packaging adoption, and regulatory support for innovative formulations. These contribute to higher CAGR projections of 8-10% in markets like India and China.

4. What are the regulatory challenges associated with adopting plastic containers for Zinacef?

Regulators require rigorous validation of stability, sterility, and bioavailability data. Compliance with Good Manufacturing Practices (GMP) and environmental regulations regarding plastic waste are also vital considerations.

5. How will antibiotic resistance impact the market projection for Zinacef?

Rising resistance elevates demand for potent broad-spectrum antibiotics like ceftriaxone, supporting sustained growth. However, resistance patterns necessitate ongoing clinical trials to verify efficacy and guide stewardship policies.


References

[1] ClinicalTrials.gov. "Ceftriaxone Stability in Plastic Containers," 2022.
[2] MarketsandMarkets. "Antibiotics Market by Type and Geography," 2023.
[3] EMA. "Guidelines on Pharmaceutical Packaging," 2021.
[4] WHO. "Global Antibiotic Resistance Surveillance," 2022.
[5] IBISWorld. "Global Healthcare Packaging Industry," 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.